Patent · US Active

Targeting glioblastoma stem cells through the TLX-TET3 axis

US10604759B2 · kind B2 · utility

0Cited by

1References

17Claims

0Family size

Assignee

City of Hope · US

Inventors

Yanhong Shi · Arcadia, US
Qi Cui · Qingdao, CN
Su Yang · Shanghai, CN

Key dates

Filing date	Jan 13, 2017
Grant date	Mar 31, 2020
Priority date	—
Expiry date	Jan 13, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2740/15043
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Methods and compositions capable of modulating activity of TLX (NR2E1), a nuclear receptor essential for neural stem cell self-renewal are provided. The modulations may comprise downregulating TLX expression and/or modulating TET3. In addition, methods of delivering shRNAs using dendrimer nanoparticles into glioblastoma stem cells are provided. The methods and compositions are useful for treating and preventing the progression of brain cancer, e.g. glioblastoma.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.